Comparative Effect of Finasteride and Dutasteride on Chromogranin A Levels

November 2010 in “ Anticancer Research ”

Alessandro Sciarra, Stefano Salciccia, Gianluca Nesi, Susanna Cattarino, Andrea Alfarone, Alessandro Gentilucci, Vincenzo Gentile

This study investigated the effects of finasteride and dutasteride on chromogranin A (CgA) serum levels in 60 men with benign prostatic hyperplasia (BPH). Participants were randomized to receive either finasteride, dutasteride, or no therapy for 6 months. Results showed that both finasteride and dutasteride significantly increased serum CgA levels at 3 and 6 months compared to the control group, indicating neuroendocrine activation. No significant difference was found between the effects of finasteride and dutasteride.

View this study on pubmed.ncbi.nlm.nih.gov →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

408 citations , May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.

Related Research

2 / 2 results

research Level-1 Data From the REDUCE Study and the PCPT Data

October 2015 in “Prostate Cancer”

Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.

research Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-Alpha Reductase Inhibitors

1 citations , January 2012 in “Daehan namseong gwahag hoeji”

Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.